%A Xue Ming, Guo Mingkun %T Effect of adoptive immunotherapy with CIK cells combined with interleukin-2 on immunologic function and life qualities of patients with nonsmall cell lung cancer %0 Journal Article %D 2015 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2015.02.003 %P 88-90 %V 42 %N 2 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9566.shtml} %8 2015-02-08 %X Objective To investigate the changes of immunologic functions and life qualities after the autocytokine induced killer (CIK) cells combined with interleukin2(IL2) being transfused back to the patients with nonsmall cell lung cancer (NSCLC). MethodsThirtyeight NSCLC patients were enrolled, and 19 patients received not only chemotherapy and radiotherapy but also adoptive immunotherapy with CIK cells combined with IL2 compared with the other 19 patients who only accepted radiotherapy and chemotherapy. The changes of immunologic functions and life qualities after the CIK cells combined with IL2 being transfused back to the patients with NSCLC were observed. Immune targets of the treatment group and control group, such as peripheral blood CD3+, CD4+, CD8+ T cell percentage, ratio of CD4+/CD8+ and Th1/Th2, were observed at the end and after 3 month of the radiation and chemotherapy. ResultsBoth of the two groups were neither having obvious adverse reactions. After CIK cells combined with IL2 treatment, the life qualities of patients improved, such as 18 cases of mental improvement, 15 cases of appetite improvement, 12 cases of sleep improvement, and 3 cases of fatigue symptoms improvement. The percentage of CD3+, CD4+ cells in the treatment group increased ［（66.39±9.22）% vs （42.98±7.23）%， t=5.45，P=0.00；（32.27±3.75）% vs （26.38±2.51）%， t=5.73，P=0.00］, the percentage of CD8+ cells declined ［（17.51±1.85）% vs （20.90±2.31）%， t=5.21，P=0.00］, the rate of CD4+/CD8+ increased and the rate of Th1/Th2 obversed ［（1.86±0.32） vs （1.27±0.19）， t=7.13，P=0.00；（1.15±0.48） vs （0.91±0.30）， t=2.42，P=0.02］. There were significant differences between the two groups. ConclusionAdoptive immunotherapy with CIK cells combined with IL2 is safe in clinical, which can improve the immunologic functions and life qualities of the patients with NSCLC.